27Jul 2023
Distinct scleroderma autoantibody profiles stratify patients for cancer risk at scleroderma onset and during the disease course

Distinct scleroderma autoantibody profiles stratify patients for cancer risk at scleroderma onset and during the disease course

The study 676 scleroderma cancer cases and 687 scleroderma controls without cancer. Anti-POLR3 and monospecific anti-Ro52 were linked to increased overall cancer risk, while anti-centromere and anti-U1RNP were associated with lower risk. These immune responses also influenced the risk of cancer-associated scleroderma. Combining certain antibodies showed the potential in decreasing cancer risk. The findings suggest that specific scleroderma immune responses could help identify cancer risk among patients.

  • #rheumatology

Like

Save

Share